Overview: Therapeutic Biomarkers in Cancer - Therapeutic Biomarkers in Cancer - page 26

41. Chapman, P.B. Improved survival with vemurafenib in melanoma

with BRAF V600E mutation.

et al.

N Engl J Med 364, 2507-2516 (2011).

42. Nazarian, R., Melanomas acquire resistance to B-RAF(V600E)

inhibition by RTK or N-RAS upregulation.

et al.

Nature 468 , 973-977

(2010).
43. ZELBORAF TM (vemurafenib) label: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2011/202429s000lbl.pdf.
44. Tarceva (erlotinib) Label: http://www.accessdata.fda.gov/drugsatfda_
docs/label/2010/021743s14s16lbl.pdf.
45. Lynch, T.J., Activating mutations in the epidermal growth factor

receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib.

et al.

, 2129-2139 (2004).
46. Rosell, R., Viteri, S., Molina, M.A., Benlloch, S., and Taron, M. Epidermal
growth factor receptor tyrosine kinase inhibitors as first-line treatment
in advanced nonsmall-cell lung cancer.

N Engl J Med 350

Curr Opin Oncol 22 , 112-120

(2010).
47. Dahabreh, I.J., Somatic EGFR mutation and gene copy gain as

predictive biomarkers for response to tyrosine kinase inhibitors in
non-small cell lung cancer.

et al.

Clin Cancer Res 16 , 291-303 (2010).

48. Keedy, V.L., American society of clinical oncology provisional

clinical opinion: epidermal growth factor receptor (EGFR) mutation
testing for patients With advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy.

et al.

J Clin

, 2121-2127 (2011).
49. Erbitux (cetuximab) Lablel: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/125084s168lbl.pdf.
50. Wong, S.F. Cetuximab: an epidermal growth factor receptor monoclonal
antibody for the treatment of colorectal cancer.

Oncol 22

Clin Ther 27 , 684-694

(2005).
51. Goldberg, R.M. Cetuximab. , S10-1 (2005).

52. Vectibix (panitumumab) Label: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/125147s080lbl.pdf.
53. Moroni, M.,

Nat Rev Drug Discov Suppl

Gene copy number for epidermal growth factor
receptor (EGFR) and clinical response to antiEGFR treatment in
colorectal cancer: a cohort study.

et al.

Lancet Oncol 6 , 279-286 (2005).

54. Chung, K.Y., Cetuximab shows activity in colorectal cancer patients

with tumors that do not express the epidermal growth factor receptor
by immunohistochemistry.

et al.

J Clin Oncol 23 , 1803-1810 (2005).